Peroxisome proliferator-activated receptor ligand MCC-555 suppresses intestinal polyps in ApcMin/+ mice via extracellular signal-regulated kinase and peroxisome proliferator-activated receptor-dependent pathways

Molecular Cancer Therapeutics

Volumn 7, Issue 9, 2008, Pages 2779-2787

  Yamaguchi, Kiyoshi ^a,f   Cekanova, Maria ^a   McEntee, Michael F ^a   Yoon, Joo Heon ^b   Fischer, Susan M ^c   Renes, Ingrid B ^d   Van Seuningen, Isabelle ^e   Baek, Seung Joon ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c UNIVERSITY OF TEXAS   (United States)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^e JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 2; NETOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INTESTINE POLYP; LUNG CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; TRANSCRIPTION INITIATION; TUMOR MODEL;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTESTINAL POLYPS; LIGANDS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MUCIN-2; MUCINS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RNA, MESSENGER; THIAZOLIDINEDIONES; TRANSCRIPTION, GENETIC;

EID: 54049158576     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0173     Document Type: Article

References (50)

1. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.
2. Koeffler HP. Peroxisome proliferator-activated receptor γ and cancers. Clin Cancer Res 2003;9:1-9.
3. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 1998;4:1046-52.
4. Nixon JB, Kamitani H, Baek SJ, Eling TE. Evaluation of eicosanoids and NSAIDs as PPARγ ligands in colorectal carcinoma cells. Prostaglandins Leukot Essent Fatty Acids 2003;68:323-30.
5. Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S, Matsuzawa Y. Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 1999;90:75-80.
6. Sarraf P, Mueller E, Smith WM, et al. Loss-of-function mutations in PPAR γ associated with human colon cancer. Mol Cell 1999;3:799-804.
7. Baek SJ, Wilson LC, Hsi LC, Eling TE. Troglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) ligand, selectively induces the early growth response-1 gene independently of PPARγ. A novel mechanism for its anti-tumorigenic activity. J Biol Chem 2003;278:5845-53.
8. Lee KS, Park JH, Lee S, Lim HJ, Jang Y, Park HY. Troglitazone inhibits endothelial cell proliferation through suppression of casein kinase 2 activity. Biochem Biophys Res Commun 2006;346:83-8.
9. Chintharlapalli S, Papineni S, Safe S. 1,1-Bis(3′-indolyl)-1-(p- substituted phenyl) methanes inhibit colon cancer cell and tumor growth through PPARγ-dependent and PPARγ-independent pathways. Mol Cancer Ther 2006;5:1362-70.
10. Chintharlapalli S, Papineni S, Baek SJ, Liu S, Safe S. 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl) methanes are peroxisome proliferator-activated receptor γ agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1. Mol Pharmacol 2005;68:1782-92.
11. Shiau CW, Yang CC, Kulp SK, et al. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARγ. Cancer Res 2005;65:1561-9.
12. Shimada T, Kojima K, Yoshiura K, Hiraishi H, Terano A. Characteristics of the peroxisome proliferator activated receptor γ (PPARγ) ligand induced apoptosis in colon cancer cells. Gut 2002;50:658-64.
13. Baek SJ, Kim JS, Nixon JB, DiAugustine RP, Eling TE. Expression of NAG-1, a transforming growth factor-β superfamily member, by troglitazone requires the early growth response gene EGR-1. J Biol Chem 2004;279:6883-92.
14. Cekanova M, Yuan JS, Li X, Kim K, Baek SJ. Gene alterations by peroxisome proliferator-activated receptor γ agonists in human colorectal cancer cells. Int J Oncol 2008;32:809-19.
15. Gupta RA, Brockman JA, Sarraf P, Willson TM, DuBois RN. Target genes of peroxisome proliferator-activated receptor γ in colorectal cancer cells. J Biol Chem 2001;276:29681-7.
16. Chiu CH, McEntee MF, Whelan J. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res 1997;57:4267-73.
17. Corpet DE, Pierre F. Point: from animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003;12:391-400.
18. Niho N, Takahashi M, Kitamura T, et al. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res 2003;63:6090-5.
19. Osawa E, Nakajima A, Wada K, et al. Peroxisome proliferator-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003;124:361-7.
20. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998;4:1053-7.
21. Masubuchi Y. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab Pharmacokinet 2006;21:347-56.
22. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 2004;23:77-99.
23. Ajioka Y, Watanabe H, Jass JR. MUC1 and MUC2 mucins in flat and polypoid colorectal adenomas. J Clin Pathol 1997;50:417-21.
24. Ogata S, Uehara H, Chen A, Itzkowitz SH. Mucin gene expression in colonic tissues and cell lines. Cancer Res 1992;52:5971-8.
25. Weiss AA, Babyatsky MW, Ogata S, Chen A, Itzkowitz SH. Expression of MUC2 and MUC3 mRNA in human normal, malignant, and inflammatory intestinal tissues. J Histochem Cytochem 1996;44:1161-6.
26. Velcich A, Yang W, Heyer J, et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002;295:1726-9.
27. Reginato MJ, Bailey ST, Krakow SL, et al. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties. J Biol Chem 1998;273:32679-84.
28. Yamaguchi K, Lee SH, Eling TE, Baek SJ. A novel peroxisome proliferator-activated receptor γ ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells. Mol Cancer Ther 2006;5:1352-61.
29. Mesquita P, Jonckheere N, Almeida R, et al. Human MUC2 mucin gene is transcriptionally regulated by Cdx homeodomain proteins in gastrointestinal carcinoma cell lines. J Biol Chem 2003;278:51549-56.
30. van der Sluis M, Melis MHM, Jonckheere N, et al. The murine Muc2 mucin gene is transcriptionally regulated by the zinc-finger GATA-4 transcription factor in intestinal cells. Biochem Biophys Res Commun 2004;325:952-60.
31. Yamaguchi K, Lee SH, Kim JS, Wimalasena J, Kitajima S, Baek SJ. Activating transcription factor 3 and early growth response 1 are the novel targets of LY294002 in a phosphatidylinositol 3-kinase-independent pathway. Cancer Res 2006;66:2376-84.
32. McEntee MF, Chiu CH, Whelan J. Relationship of β-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice. Carcinogenesis 1999;20:635-40.
33. Yamazaki K, Shimizu M, Okuno M, et al. Synergistic effects of RXRα and PPARγ ligands to inhibit growth in human colon cancer cells - phosphorylated RXRα is a critical target for colon cancer management. Gut 2007;56:1557-63.
34. Perrais M, Pigny P, Copin M-C, Aubert J-P, Van Seuningen I. Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1. J Biol Chem 2002;277:32258-67.
35. Bren-Mattison Y, Meyer AM, Van Putten V, et al. Antitumorigenic effects of peroxisome proliferator-activated receptor-γ (PPARγ) in non-small cell lung cancer cells (NSCLC) are mediated by suppression of COX-2 via inhibition of NF-κB. Mol Pharmacol 2008;73:709-17.
36. Rumi MA, Ishihara S, Kadowaki Y, et al. Peroxisome proliferator-activated receptor γ-dependent and -independent growth inhibition of gastrointestinal tumour cells. Genes Cells 2004;9:1113-23.
37. Fujimura T, Kimura C, Oe T, et al. A selective peroxisome proliferator-activated receptor γ modulator with distinct fat cell regulation properties. J Pharmacol Exp Ther 2006;318:863-71.
38. Im SS, Kim JW, Kim TH, et al. Identification and characterization of peroxisome proliferator response element in the mouse GLUT2 promoter. Exp Mol Med 2005;37:101-10.
39. Motojima K. Differential effects of PPARα activators on induction of ectopic expression of tissue-specific fatty acid binding protein genes in the mouse liver. Int J Biochem Cell Biol 2000;32:1085-92.
40. Lee HW, Ahn DH, Crawley SC, et al. Phorbol 12-myristate 13-acetate up-regulates the transcription of MUC2 intestinal mucin via Ras, ERK, and NF-κB. J Biol Chem 2002;277:32624-31.
41. Brockman JA, Gupta RA, Dubois RN. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 1998;115:1049-55.
42. Clay CE, Namen AM, Atsumi G, et al. Magnitude of peroxisome proliferator-activated receptor-γ activation is associated with important and seemingly opposite biological responses in breast cancer cells. J Investig Med 2001;49:413-20.
43. Sakamoto J, Kimura H, Moriyama S, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000;278:704-11.
44. Kumagai T, Ikezoe T, Gui D, et al. RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-γ ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide. Clin Cancer Res 2004;10:1508-20.
45. Vincent A, Perrais M, Desseyn JL, Aubert JP, Pigny P, Van Seuningen I. Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells. Oncogene 2007;26:6566-76.
46. Blache P, van de Wetering M, Duluc I, et al. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol 2004;166:37-47.
47. Ookawa K, Kudo T, Aizawa S, Saito H, Tsuchida S. Transcriptional activation of the MUC2 gene by p53. J Biol Chem 2002;277:48270-5.
48. Park S, Park CH, Hahm ER, et al. Activation of Raf1 and the ERK pathway in response to L-ascorbic acid in acute myeloid leukemia cells. Cell Signal 2005;17:111-9.
49. Xiao D, Choi S, Johnson DE, et al. Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2. Oncogene 2004;23:5594-606.
50. Li M, Lee TW, Yim AP, Mok TS, Chen GG. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-γ- and ERK-dependent in human non-small lung cancer cells. J Cell Physiol 2006;209:428-38.